TrkAIII: A novel hypoxia-regulated alternative TrkA splice variant of potential physiological and pathological importance

Cell Cycle

Volumn 4, Issue 1, 2005, Pages 8-9

  Tacconelli, Antonella ^a   Farina, Antonietta R ^a   Cappabianca, Lucia ^a   Gulino, Alberto ^b,c   Mackay, Andrew R ^a,d  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c IRCCS NEUROMED   (Italy)

^d UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

Hypoxia; Neuroblastoma neural stem cells; Splice variation; TrkA; Tumor progression

Indexed keywords

NERVE GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE A;

ALTERNATIVE RNA SPLICING; APOPTOSIS; CELL DIFFERENTIATION; CELL MATURATION; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM; HUMAN; HUMAN CELL; HYPOXIA; NEURAL CREST; PATHOPHYSIOLOGY; PERIPHERAL NERVOUS SYSTEM; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SHORT SURVEY; SIGNAL TRANSDUCTION; STEM CELL;

EID: 22844451845     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.4.1.1349     Document Type: Short Survey

References (34)

1. Martin-Zanca D, Oskam R, Mitra G, Copeland T, Barbacid M. Molecular and biochemical characterisation of the human Trk oncogene. Mol Cell Biol 1989; 9:24-33.
2. Klein R, Jing S, Nanduri V, O'Rourke E, Barbacid M. The trk proto-oncogene encodes a receptor for nerve growth factor. Cell 1991; 65:189-97.
3. Bibel M, Barde YA. Neurotrophins: Key regulators of cell fate and cell shape in the vertebrate nervous system. Genes Dev 2000; 14:2919-37.
4. Oppenheim RW. Cell death during development of the nervous system. Annu Rev Neurosci 1991; 14:453-501.
5. Yao R, Cooper GM. Requirement for phosphoinositol-3 kinase in the prevention of apoptosis by nerve growth factor. Science 1995; 267:2003-05.
6. Obermeier A, Bradshaw RA, Seedorf K, Choidas A, Schlessinger J, Ullrich A. Neuronal differentiation signals are controlled by nerve growth factor receptor/Trk binding sites for SHC and PLC gamma. EMBO J 1994; 13:1585-90.
7. Greco A, Villa R, Pierotti MA. Genomic organisation of the human NTRK1 gene. Oncogene 1996; 13:2463-6.
8. Barker PA, Lomen-Hoerth C, Gensch EM, Meakin SO, Glass DJ, Shooter EM. Tissue specific alternative splicing generates two isoforms of the TrkA receptor. J Biol Chem 1993; 268:15150-7.
9. Kaplan DR, Stephens RM. Neurotrophin signal transduction by the Trk receptor. J Neurobiol 1994; 25:1404-17.
10. Cunningham ME, Stephens RM, Kaplan DR, Greene LA. Autophosphorylation of activation loop tyrosines regulates signalling by the Trk nerve growth factor receptor. J Biol Chem 1997; 272:10957-67.
11. Hallberg B, Ashcroft M, Loeb DM, Kaplan DR. Nerve growth factor induced stimulation of Ras requires Trk interaction with She but does not involve phosphoinositide 3-OH kinase. Oncogene 1998; 17:691-7.
12. Meakin SO, MacDonald JIS, Gryz EA, Kubu CJ, Verdi JM. The signalling adapter FRS-2 competes with She for binding to the nerve growth factor receptor TrkA. A model discriminating between proliferation and differentiation. J Biol Chem 1999; 274:9861-70.
13. Segal RA, Bhattacharya A, Rua LA, Alberta JA, Stephens RM, Kaplan DR, et al. Differential utilization of Trk autophosphorylation sites. J Biol Chem 1996; 271:20175-81.
14. Martin-Zanca D, Hughes SH, Barbacid M. A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences. Nature 1986; 319:743-8.
15. Oskam R, Coulier F, Ernst M, Martin-Zanca D, Barbacid M. Frequent generation of oncogenes by in vitro recombination of Trk protoncogene sequences. Proc Natl Acad Sci USA 1988; 85:2964-8.
16. Coulier F, Kumar R, Ernst M, Klein R, Martin-Zanca D, Barbacid M. Human Trk oncogenes activated by point mutation, in-frame deletion, and duplication of the tryrosine kinase domain. Mol Cell Biol 1990; 10:4202-10.
17. Butti MG, Bongarzone I, Ferraresi G, Mondellini P, Borrello MG, Pierotti MA. A sequence analysis of the genomic regions involved in the rearrangements between TPM3 and NTRK1 genes producing TRK oncogenes in papillary thyroid carcinomas. Genomics 1995; 28:15-24.
18. George DJ, Suzuki H, Bova SG, Isaacs JT. Mutational analysis of the TrkA gene in prostate cancer. The prostate 1998; 36:172-80.
19. Reuther GW, Lambert QT, Caligiuri MA, Der CJ. Identification and characterisation of an activating TrkA deletion mutation in acute myeloid leukemia. Mol Cell Biol 2000; 20:8655-66.
20. In: Brodeur GM, Sawada TS, Tsuchida PA, eds. "Neuroblastoma". Amsterdam Holland: Voute Elsevier Press, 2000.
21. Nakagawara A, Arima M, Azar CG, Scavarla NJ, Brodeur GM. Inverse relationship between trk expression and N-myc amplification in human neuroblastoma. Cancer Res 1992; 52:1364-8.
22. Matsushima H, Bogenmann E. Nerve growth factor (NGF) induces neuronal differentiation in neuroblastoma cells transfected with the NGF receptor cDNA. Mol Cell Biol 1990; 10:5015-20.
23. Lavenius E, Gestblom C, Johansson I, Nanberg E, Pahlmen S. Transfection of TrkA into human neuroblastoma cells restores ability to differentiate in response to nerve growth factor. Cell Growth Differ 1995; 6:727-36.
24. Lucarelli E, Kaplan D, Thiele CJ. Activation of trk-A but not trk-B signal transduction pathway inhibits growth of neuroblastoma cells. Eur J Cancer 1997; 33:2068-70.
25. Eggert A, Grotzer MA, Ikegaki N, Liu XG, Evans AE, Brodeur GM. Expression of the neurotrophin receptor TrkA downregulates expression and function of angiogenic stimulators in SH-SY5Y neuroblastoma cells. Cancer Res 2002; 62:1802-8.
26. Scaruffi P, Cusano R, Dagnino M, Tonini GP. Detection of DNA polymorphisms and point mutations of high affinity nerve growth factor receptor (TrkA) in human neuroblastoma. Int J Oncol 1999; 14:935-8.
27. Tacconelli A, Farina AR, Cappabianca L, DeSantis G, Tessitore A, Vetuschi A, Sferra R, Rucci N, Argent B, Screpanti I, Gulino A, Mackay AR. TrkA alternative splicing: A regulated tumor-promoting switch in neuroblastoma. Cancer Cell 2004; 6:347-60.
28. Watson FL, Porcionatto MA, Bhattacharyya A, Stiles C, Segal RA. TrkA glycosylation regulates localisation and activity. J Neurobiol 1999; 39:323-36.
29. Urfer R, Tsoulfas P, O'Conell L, Shelton D, Parada LF, Presta LG. An immunoglobulin-like domain determines the specificity of neurotrophin receptors. EMBO J 1995; 14:2795-805.
30. Arevalo JC, Conde B, Hempstead BL, Chao MV, Matrin-Zanca D, Perez P. TrkA immunoglobulin-like ligand binding domains inhibit spontaneous activation of the receptor. Mol Cell Biol 2000; 20:5908-16.
31. Barakat MT, Meeran K, Bloom SR. Neuroendocrine Tumours. Endocrine-Related. Cancer 2004; 11:1-8.
32. Rodriguez-Manzaneque JC, Lane TF, Ortega MA, Hynes RO, Lawler J, Iruela-Arispe ML. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc Natl Acad Sci USA 2001; 98:12485-90.
33. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000; 2:737-44.
34. Harris AL. Hypoxia-a key regulatory factor in tumor growth. Nature Rev Cancer 2002; 2:38-47.